Ahhyung Choi

Ahhyung Choi

Auto-generated profile, based on publicly available information

Ahhyung Choi

School of Pharmacy, Sungkyunkwan University, Suwon, Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2022 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
YNYunha Noh
Yunha Noh
HLHyesung Lee
Hyesung Lee
ACAhhyung Choi
Ahhyung Choi
JKJun Soo Kwon
Jun Soo Kwon
SCSeung-Ah Choe
Seung-Ah Choe
JSJu-Young Shin
Ju-Young Shin
Background: Benzodiazepines are frequently prescribed during pregnancy; however, evidence about possible teratogenicity is equivocal. We aimed to evaluate the association between first-trimester benzodiazepine use and the risk of major congenital malformations.Methods and findings: Using Korea’s nationwide healthcare database, we conducted a population-based cohort study of women who gave birth during 2011 to 2018 and their live-born infants. The exposure was defined as one or more benzodiazepine prescriptions during the first trimester. We determined the relative risks (RRs) and confidence intervals (CIs) of overall congenital malformations and 12 types of organ-specific malformations. Infants were followed from birth to death or 31 December 2019, whichever came first (up to 8 years of age). Propensity score fine stratification was employed to control for 45 potential confounders. Among a total of 3,094,227 pregnancies, 40,846 (1.3%) were exposed to benzodiazepines during the first trimester (mean [SD] age, 32.4 [4.1] years). The absolute risk of overall malformations was 65.3 per 1,000 pregnancies exposed to benzodiazepines versus 51.4 per 1,000 unexposed pregnancies. The adjusted RR was 1.09 (95% CI 1.05 to 1.13,p< 0.001) for overall malformations and 1.15 (1.10 to 1.21,p< 0.001) for heart defects. Based on mean daily lorazepam-equivalent doses, the adjusted RRs for overall malformations and heart defects were 1.05 (0.99 to 1.12,p= 0.077) and 1.12 (1.04 to 1.21,p= 0.004) for <1 mg/day and 1.26 (1.17 to 1.36,p< 0.001) and 1.31 (1.19 to 1.45,p< 0.001) for >2.5 mg/day doses, respectively, suggesting a dose–response relationship. A small but significant increase in risk for overall and heart defects was detected with several specific agents (range of adjusted RRs: 1.08 to 2.43). The findings were robust across all sensitivity analyses, and negative control analyses revealed a null association. Study limitations include possible exposure misclassification, residual confounding, and restriction to live births.Conclusions: In this large nationwide cohort study, we found that first-trimester benzodiazepine exposure was associated with a small increased risk of overall malformations and heart defects, particularly at the higher daily dose. The absolute risks and population attributable fractions were modest. The benefits of benzodiazepines for their major indications must be considered despite the potential risks; if their use is necessary, the lowest effective dosage should be prescribed to minimize the risk.Trial registration: ClinicalTrials.gov NCT04856436.

1 March 2023 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
YNYunha Noh
Yunha Noh
HJHan Eol Jeong
Han Eol Jeong
ACAhhyung Choi
Ahhyung Choi
ECEun-Young Choi
Eun-Young Choi
BPBjörn Pasternak
Björn Pasternak
JSJu-Young Shin
Ju-Young Shin
The prevalence of allergic diseases has risen worldwide, especially among children and adolescents.1,2 Great efforts have been dedicated to identifying factors associated with allergic disease,3 and data have suggested associations between allergic diseases and acid-suppressive medication (ASM) use in fetal and early life.4-8 Meanwhile, ASMs, including proton pump inhibitors (PPIs) and histamine 2 receptor antagonists (H2RAs), are frequently used during pregnancy to treat gastroesophageal reflux disease (GERD),9 and in recent decades, the use of ASMs has substantially increased in both pregnant and pediatric populations.10,11

27 February 2023 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
ECEun-Young Choi
Eun-Young Choi
HJHan Eol Jeong
Han Eol Jeong
YNYunha Noh
Yunha Noh
ACAhhyung Choi
Ahhyung Choi
DYDong Keon Yon
Dong Keon Yon
JSJu-Young Shin
Ju-Young Shin
Background: Existing data on the use of nonsteroidal anti-inflammatory drugs (NSAIDs) during late pregnancy is well established, providing assurance. However, the use of NSAIDs during early pregnancy remains inconclusive owing to conflicting findings on adverse neonatal outcomes as well as the limited data on adverse maternal outcomes. Therefore, we sought to investigate whether early prenatal exposure to NSAIDs was associated with neonatal and maternal adverse outcomes. Methods and findings: We conducted a nationwide, population-based cohort study using Korea’s National Health Insurance Service (NHIS) database with a mother–offspring cohort constructed and validated by the NHIS to include all live births in women aged 18 to 44 years between 2010 and 2018. We defined exposure to NSAIDs as at least two records of NSAID prescriptions during early pregnancy (first 90 days of pregnancy for congenital malformations and first 19 weeks for nonmalformation outcomes) and compared against three distinct referent groups of (1) unexposed, no NSAID prescription during the 3 months before pregnancy start to end of early pregnancy; (2) acetaminophen-exposed, at least two acetaminophen prescriptions during early pregnancy (i.e., active comparator); and (3) past users, at least two NSAID prescriptions before the start of pregnancy but no relevant prescriptions during pregnancy. Outcomes of interest were adverse birth outcomes of major congenital malformations and low birth weight and adverse maternal outcomes of antepartum hemorrhage and oligohydramnios. We estimated relative risks (RRs) with 95% CIs using generalized linear models within a propensity score (PS) fine stratification weighted cohort that accounted for various potential confounders of maternal sociodemographic characteristics, comorbidities, co-medication use, and general markers of burden of illness. Of 1.8 million pregnancies in the PS weighted analyses, exposure to NSAIDs during early pregnancy was associated with slightly increased risks for neonatal outcomes of major congenital malformations (PS-adjusted RR, 1.14 [CI, 1.10 to 1.18]) and low birth weight (1.29 [1.25 to 1.33]), and for maternal outcome of oligohydramnios (1.09 [1.01 to 1.19]) but not antepartum hemorrhage (1.05 [0.99 to 1.12]). The risks of overall congenital malformations, low birth weight, and oligohydramnios remained significantly elevated despite comparing NSAIDs against acetaminophen or past users. Risks of adverse neonatal and maternal outcomes were higher with cyclooxygenase-2 selective inhibitors or use of NSAIDs for more than 10 days, whereas generally similar effects were observed across the three most frequently used individual NSAIDs. Point estimates were largely consistent across all sensitivity analyses, including the sibling-matched analysis. Main limitations of this study are residual confounding by indication and from unmeasured factors. Conclusions: This large-scale, nationwide cohort study found that exposure to NSAIDs during early pregnancy was associated with slightly higher risks of neonatal and maternal adverse outcomes. Clinicians should therefore carefully weigh the benefits of prescribing NSAIDs in early pregnancy against its modest, but possible, risk of neonatal and maternal outcomes, where if possible, consider prescribing nonselective NSAIDs for <10 days, along with continued careful monitoring for any safety signals.

3 January 2023 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
ACAhhyung Choi
Ahhyung Choi
YNYunha Noh
Yunha Noh
HJHan Eol Jeong
Han Eol Jeong
ECEun-Young Choi
Eun-Young Choi
KMKenneth K. C. Man
Kenneth K. C. Man
JSJu-Young Shin
Ju-Young Shin
Gastroesophageal reflux disease (GERD) is common during pregnancy, occurring in up to 80% of the pregnant population.1 Although mild symptoms can be alleviated by lifestyle modifications, acid-suppressive medications are often required for a substantial number of patients to manage their inadequately controlled symptoms. Specifically, the use of proton pump inhibitors (PPIs) during pregnancy has increased worldwide, which may be in part due to their acid-suppressing effects.2,3

1 January 2024 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
DKDayeon Kang
Dayeon Kang
ACAhhyung Choi
Ahhyung Choi
SPSuneun Park
Suneun Park
SCSeung-Ah Choe
Seung-Ah Choe
JSJu-Young Shin
Ju-Young Shin
Kang D, et al. J Korean Med Sci. 2023 Nov;39(1):e3. https://doi.org/10.3346/jkms.2024.39.e3

24 April 2023 in COPD: Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
JCJing Chen
Jing Chen
JSJu-Young Shin
Ju-Young Shin
HKHyungwoo Kim
Hyungwoo Kim
JKJu Hwan Kim
Ju Hwan Kim
ACAhhyung Choi
Ahhyung Choi
SSSumitra Shantakumar
Sumitra Shantakumar
A retrospective cohort study was conducted to examine trends in the incidence and burden of pertussis among adults ≥50 years in South Korea, with/without pre-existing chronic obstructive pulmonary disease (COPD) or asthma. The nationwide Health Insurance Review and Assessment Service (HIRA) database was used to identify patients ≥50 years diagnosed with pertussis (2009–2018). Mean annual incidence of pertussis per 100 000 persons and overall mean incidence rate ratios (IRR) were calculated for patients with pre-existing COPD or asthma versus those with neither. Incremental healthcare costs (all-cause and pertussis-related) and healthcare utilisation (number of outpatient visits, emergency room visits, and number and length of hospitalisations) up to 12 months after, compared to 3 months before pertussis diagnosis, were also measured for each group (matched on sex, age, and Charlson Comorbidity Index). Of 1011 pertussis cases, 175 had asthma, 96 had COPD (not mutually exclusive), and 796 had neither. Overall mean pertussis incidence was 2.5, 3.4, and 0.5 for adults with pre-existing COPD, asthma, and those with neither. IRR (95% confidence interval) of pertussis for adults with pre-existing COPD and asthma was 4.9 (4.0–‍6.1) and 6.7 (5.7–7.9). Both COPD-pertussis and asthma-pertussis groups had higher mean incremental all-cause costs and length of hospitalisations than the general-pertussis group 3 months following pertussis diagnosis. In conclusion, individuals ≥50 years in South Korea with pre-existing COPD or asthma were at an increased risk of being diagnosed with pertussis and had higher healthcare resource utilisation than those without these conditions.